معرفی
David Poole serves as a Research Associate in the Department of Chemistry and Pharmaceutical Sciences within the Faculty of Science at Vrije Universiteit Amsterdam, affiliated with the Amsterdam Institute of Molecular and Life Sciences (AIMMS). His research bridges experimental and computational chemistry with active publications through 2025.
His scientific fingerprint reveals deep expertise in supramolecular assembly (100% nanosphere formation), peptide macrocyclization (72%), and transition metal chemistry (72% ruthenium/palladium systems). Key research areas include:
- Nanoscale self-assembly mechanisms using pseudorotaxane templates
- Computational design of venom inhibitors targeting phospholipase A2
- Electrocatalytic nitrate-to-ammonia conversion for environmental remediation
- Engineering coagulation factors to overcome anticoagulant therapies
- Spontaneous peptide cyclization during ribosomal synthesis
Analysis of his 13 publications (2023-2025) shows strong interdisciplinary convergence between inorganic synthesis, computational modeling, and biomedical applications, particularly in drug discovery and nanomaterial design. His Nature Chemistry (2025) work demonstrates innovative strategies for reducing pathway complexity in nanosphere assembly, while his venom inhibitor research addresses global snakebite treatment challenges.
Poole actively contributes to education through the course Current Topics in Computational Medicinal Chemistry and Toxicology (2025-2026), supervising advanced graduate topics in computational drug design. His research network spans international collaborations in electrocatalysis and toxinology, with significant Mendeley readership (12+ for key publications) and media coverage including 3 news outlets and 20+ X mentions.
As part of AIMMS, he participates in Amsterdam's molecular life sciences ecosystem focusing on drug discovery and chemical biology. Current projects integrate computational modeling with synthetic chemistry to develop therapeutic candidates and functional nanomaterials, with recent work on factor X engineering showing translational potential for anticoagulant reversal therapies.
